News

RTsafe’s core role for the development of German guidelines for a standard, safe and efficient implementation of Single-Isocentric Multi-Focal SRS throughout the country 

03February 2022

ATHENS, Greece, February 3, 2022  

RTsafe is happy to announce that its PRIME and Pseudopatient 3D phantoms, have been selected by a consortium of high-end German Radiotherapy Institutions – led by the Division of Medical Physics of the Department of Radiation Oncology at the Medical Center of University of Freiburg – towards supporting a study whose results will be used for the development of national guidelines in Germany for a safe and efficient implementation of Single Isocentric – Multi Focal SRS (SIMF SRS). The study is funded by the German Cancer Aid (Deutsche Krebshilfe).

SIMF SRS is probably the most complex radiotherapy technique. It allows precise and time efficient treatment of patients with multiple brain metastasis (20%-40% of all cancer patients will develop brain metastasis). Whilst more complex treatments usually translate to more targeted treatments, at the same time they require more complex planning and End-to-End Quality Assurance. Researchers throughout numerous radiotherapy institutions in Germany will evaluate independently all sources of errors in SIMF SRS through an End-to-End manner using RTsafe’s PRIME and PseudoPatient 3D phantoms. These, are 3D-printed head phantoms, based on real patient’s CT data using bone and soft tissue-equivalent materials, that are treated as real patients. The applied radiation dose will be measured using 3D polymer gel dosimetry and magnetic resonance imaging.

This study aims to determine for the first time, precisely, how the location, size, and number of targets affect the accuracy (spatial and dosimetric) of treatment delivery. All the above will be followed by corresponding measurements in many radiotherapy centers across Germany to examine the differences between the protocols currently used in treatment planning and delivery for this radiation technique. Based on the study outcome, general guidelines in Germany for individualized patient treatment delivery QA and machine QA for an overall safe and efficient treatment will be developed.

“RTsafe’s core role in this project makes our team very proud and certainly goes in line with the company’s aim to have an increasingly significant impact in the field of Radiosurgery globally.” said Prof. Dr. Pappas, founder, and CSO of RTsafe. “I am confident that our solutions and team will fulfil the requirements of this challenging study and will support its aims and milestones.”

The study will have a duration of 3 years.

 

Press to download the Press Release

 

About RTsafe

RTsafe is a medical technology company that has developed a unique approach to quality assurance that significantly enhances the safety and accuracy of radiotherapy for cancer and other medical conditions. It combines proven expertise in medical physics with highly accurate 3D printing technology to create pseudo‐in‐vivo dosimetry phantoms for End‐to‐End commissioning, benchmarking and patient‐specific quality assurance in SRS, IMRT, VMAT and SBRT applications. The anatomically accurate models enable medical professionals to plan more precise treatment interventions for individual patient and help radiotherapy industry to fine-tune its products. The result is more effective individualized therapy and reduced patient risk. For more information, visit www.rt-safe.com.

For media inquiries, please contact Ms. Marianna Liondou | +30 6944 360 641 | [email protected]

 

 

Explore our Products
& Services
  • 19September 2022

    RTsafe to Exhibit at ASTRO 2022 in San Antonio

    Read More
  • 18May 2022

    RTsafe to exhibit at ISRS Congress 2022 in Milan

    Read More

Request a quote

ΕΣΠΑ Banner